52121-98-9

Basic information

• Product Name: Benzene, (6-iodohexyl)-
• CAS NO: 52121-98-9
• Molecular Formula: C12H17I
• Molecular Weight: 288.171
• Mol File: 52121-98-9.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: Benzene, (6-iodohexyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, (6-iodohexyl)-(52121-98-9)
• EPA Substance Registry System: Benzene, (6-iodohexyl)-(52121-98-9)

Safety Data

• Hazardous Substances Data: 52121-98-9(Hazardous Substances Data)

Upstream product

• 593-71-5 Chloroiodomethane 
• 1462-75-5 3-phenylpropylmagnesium bromide 
• 288-32-4 1H-imidazole 
• 2430-16-2 6-phenyl-1-hexanol 
• 61440-48-0 6-phenylhexanol methylsulfonyl ester 
• 27976-27-8 (6-bromohexyl)benzene 
• 71-43-2 benzene 
• 22809-37-6 6-bromohexanoyl chloride 

Downstream Products

• 802919-99-9 1,1-difluoro-7-phenylheptyl phenyl sulfone 
• 408342-50-7 2,2-dimethyl-8-phenyl-octanoic acid methyl ester 
• 52122-33-5 4-(6-phenylhexyl)-3,5-heptanedione 
• 1202760-70-0 6-phenylhexane-1-sulfonyl chloride 

Relevant articles and documents

Sulfonyl fluoride inhibitors of fatty acid amide hydrolase

Sulfonyl fluorides are known to inhibit esterases. Early work from our laboratory has identified hexadecyl sulfonylfluoride (AM374) as a potent in vitro and in vivo inhibitor of fatty acid amide hydrolase (FAAH). We now report on later generation sulfonyl

Azetidinone derivatives for the treatment of atherosclerosis

PCT No. PCT/EP95/04202 Sec. 371 Date Sep. 30, 1997 Sec. 102(e) Date Sep. 30, 1997 PCT Filed Oct. 25, 1995 PCT Pub. No. WO96/13484 PCT Pub. Date May 9, 1996Azetidinone derivatives of formula (I) in which R1 and R2, which may be the same or different, is each selected from hydrogen or C(1-8)alkyl; R3 is C(1-8)alkyl or C(3-8)cycloalkyl each of which may be optionally substituted; X is a linker group; Y is an aryl group; and n is 0, 1 or 2; and excluding benzyl (4-methylthio-2-oxo-azetidin-1-yl)acetate are inhibitors of the enzyme Lp PLA2 and are of use in therapy, in particular treating atherosclerosis.

2-amino-1,3-propanediol compound and immunosuppressant

2-Amino-1,3-propanediol compounds of the formula (I) STR1 wherein R is an optionally substituted straight- or branched carbon chain, an optionally substituted aryl, an optionally substituted cycloalkyl or the like, and R2, R3, R4 and R5 are the same or different and each is a hydrogen, an alkyl, an aralkyl, an acyl or an alkoxycarbonyl, pharmaceutically acceptable salts thereof and immunosuppressants comprising these compounds as active ingredients. The 2-amino-1,3-propanediol compounds of the present invention show immunosuppressive action and are useful for suppressing rejection in organ or bone marrow tranplantation, prevention and treatment of autoimmune diseases or as reagents for use in medicinal and pharmaceutical fields.